---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059097"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:03:35.176148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acrivon Q1 net loss $16.5M; ACR-368 Phase 2b 50% ORR; $130M PIPE

## Summary
- Net loss $16.5M vs $12.8M YoY; R&D $11.5M, G&A $6.2M.
- ACR-368 Phase 2b: 50% confirmed ORR in OncoSignature-positive patients (10) vs 0% in negative (16), p=0.0038.
- Endometrial cancer identified as new AP3-predicted sensitive tumor type; median DoR not yet reached.
- ACR-2316 IND expected Q3 2024; Phase 1 start Q4 2024.
- Closed oversubscribed $130M private placement at premium; cash ~$240M pro forma into H2 2026.

## SEC filing metadata
- accession: 0000950170-24-059097
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/0000950170-24-059097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/acrv-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059097
- JSON: https://secwatch.observer/filing/0000950170-24-059097.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059097.txt

## Key facts
- Earnings Releases
  Acrivon Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $16.5 million.
  - Period: first quarter ended March 31, 2024
  - Net income: $16.5 million
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2024 was $16.5 million compared to a net loss of $12.8 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781174/000095017024059097/0000950170-24-059097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.